Cancer Advances
Subscribe:
Featured Episode
The Potential of CAR T-Cell Therapy for Chronic Lymphocytic Leukemia (CLL)
Vice Chair of the Center for Immunotherapy and Precision Immuno-Oncology, J. Joseph Melenhorst, PhD, joins the Cancer Advances Podcast to discuss the potential of CAR T-cell therapy for chronic lymphocytic leukemia (CLL). Listen as Dr. Melenhorst explains how advancements in cell therapy are overcoming challenges like T cell exhaustion, improving response rates, and how novel approaches could improve treatment outcomes.
Play NowAll Cancer Advances Episodes
February 13, 2025
Exploring Intermittent Therapy for Metastatic Renal Cell Carcinoma
Moshe Ornstein, MD, MA, a Genitourinary Medical Oncologist joins the Cancer Advances podcast to talk about intermittent therapy for metastatic renal cell carcinoma (mRCC). Listen as Dr. Ornstein explores the evolution of treatment options, from cytokine and targeted therapies to immunotherapy, and as he delves into the promising concept of treatment breaks to improve patient outcomes.
Play NowFebruary 6, 2025
Real-World Insights on Bispecific Antibodies for Relapsed/Refractory Large B-Cell Lymphomas
Medical Oncologist in the Lymphoid Malignancies Division, Taylor Brooks, MD, joins the Cancer Advances podcast to discuss real-world data on bispecific antibodies for relapsed or refractory large B-cell lymphomas that was presented at the 2024 American Society of Hematology (ASH) Annual Meeting. Listen as Dr. Brooks shares insights into efficacy, safety, and challenges patients face outside clinical trial parameters, and how these therapies are reshaping treatment approaches.
Play NowJanuary 30, 2025
Advancing Pelvic Sarcoma Reconstruction with 3D Printing
Lukas Nystrom, MD, Orthopaedic Oncology Surgeon and a Co-Director of the Sarcoma Program at Cleveland Clinic joins the Cancer Advances Podcast to talk about the advancements in custom 3D-printed implants for pelvic sarcoma reconstruction. Listen as Dr. Nystrom explains how these personalized implants are transforming sarcoma care by enhancing precision during tumor resections, offering tailored solutions for complex pelvic reconstructions and improving patient outcomes.
Play NowJanuary 23, 2025
Resensitizing Triple-Negative Breast Cancer: Targeting the YES1 Protein
Ruth Keri, PhD, Associate Director for Basic Research at Case Comprehensive Cancer Center and Professor of Cancer Biology at Cleveland Clinic, returns to the Cancer Advances Podcast to share the latest advancements in targeting YES1 protein to treat triple-negative breast cancer (TNBC). Listen as Dr. Keri discusses how YES1 impacts chemotherapy resistance, tumor growth, and EGFR inhibition, uncovering promising therapeutic opportunities and the potential clinical trials to improve outcomes for patients facing this aggressive cancer.
Play Now
